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Thymus evaluation is not included in the guidelines of the Histiocyte Society, so its prevalence, man-
agement and prognosis are not well established. We present a newborn with self-healing cutaneous LCH
and thymic involvement that was evaluated with a thoracic ultrasound. With the current evidence we
are unable to predict the prognosis of the thymus association in neonatal LCH. We suggest that per-
forming thymic ultrasound study, which is a non-invasive technique, would allow us to know the
incidence of thymic involvement and its role on prognosis.
© 2016 Pediatric Hematology Oncology Chapter of Indian Academy of Pediatrics. Production and hosting
by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).1. Introduction
Langerhans cell histiocytosis (LCH) is characterized by an
accumulation of clonal dendritic cells in single or multiple organs
[1]. It includes a wide spectrum of diseases with various clinical
presentations and possible outcomes, ranging from purely cuta-
neous self-healing forms to disseminated fatal cases [1]. Clinical
stratiﬁcation for LCH depends on organ involvement, single-system
disease or multi-system disease, and whether the disease involves
risk organs (liver, spleen and hematopoietic system) [2]. Cutaneous
clinical presentation during the neonatal period does not predict
the extent or course of the disease [3]. Thymus involvement in LCH
has been reported in the literature to be rare. However, screening
studies according to the Histiocyte Society do not include in a
routine basis thymus evaluation in LCH, so its prevalence, prog-
nostic value and management are not well established [2].gy, Hospital Universitari Son
allorca, Spain.
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A full term female newborn presented with multiple congenital
skin lesions. She was born by vaginal delivery after an uneventful
pregnancy. Birth weight, length and Apgar score were within
normal range. The patient was afebrile with stable vital signs and
no lymphadenopathy or hepatosplenomegaly was noted. On
physical examination, the newborn presented multiple erythema-
tous vesiculopustules and small crusted lesions in a generalized
distribution, sparing only the palms and soles (Fig. 1A). A complete
blood count with differential, serum electrolytes, liver enzymes,
creatinine and C-reactive protein were normal. Viral serologies
were negative as well as bacterial and viral cultures from skin le-
sions. Cutaneous histopathologic analysis revealed a dense inﬁl-
trate in the upper dermis of middle-size cells with large kidney-
shaped nuclei that showed epidermotropism. (Fig. 1B). Immuno-
histochemically, these cells were positive for both CD1a and S-100
protein (Fig. 1C). Staining with anti-BRAF V600E (VE1) (Ventana
Medical Systems) was homogenously positive (Fig. 1D). Diagnosis
of LCH was established and a complete work-up for systemic
involvement (laboratory analysis, skeletal and chest X-rays,
abdominal ultrasound and cranial magnetic resonance imaging)
was unremarkable. A thoracic computed tomography revealed
thymic punctate calciﬁcations (Fig. 1E) that were further bestrics. Production and hosting by Elsevier B.V. This is an open access article under the
Fig. 1. Cutaneous and thymic congenital LCH. A: Multiple congenital erythematous vesiculopustules and small crusted lesions. B: Histopathology of a skin lesion showing a dense
inﬁltrate of atypical histiocytes with epidermotropism (HE stain, original magniﬁcation x 100). C: The atypical histiocytes stained positively for CD1a (original magniﬁcation  200)
D: Staining with anti-BRAF V600E (VE1) is homogenously positive (original magniﬁcation  400) E: CT scan of mediastinum showing multiple thymic punctate calciﬁcations
(1e3 mm).
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included thymic hyperplasia, germ cell neoplasia, lymphoma, T-cell
leukemia and granulomatous disease, though they are much less
common in neonates. The presence of punctate calciﬁcations has
been described as speciﬁc for LCH [4].
During our patient's follow-up, cutaneous lesions disappeared
at 8 weeks and routine follow-up studies including full blood count,
serum and urine electrolytes, liver enzymes, creatinine, C-reactive
protein and thymic ultrasound are performed. At 9 months of age
our patient has not developed progression of LCH to other organs
and surveillance of thymic calciﬁcations with ultrasound showed a
decrease in the size and number of the lesions.3. Discussion
LCH is a rare disease that can involve almost any organ and
develop at any age. The pathogenesis of LCH remains unknown [1].
The recent demonstration of BRAFV600E and MAP2K1 gene mu-
tations in LCH samples support the neoplastic origin rather than a
reactive, inﬂammatory process or an immune dysregulation [5,6].
Both mutations imply a constitutive activation of the mitogen-
activated protein kinase (MAPK) pathway. The frequency of the
somatic BRAFV600E mutations ranges from 38% to 57% [7e9] and
mutations in MAP2K1, have been also identiﬁed in 27,5% of LCH
cases [6]. These somatic mutations can occur at different stages
during myeloid differentiation resulting in different disease forms.
When the mutation targets early myeloid progenitors, the diseasewould be highly aggressive and when it targets differentiated
dendritic cells it would lead to an attenuated phenotype [10]. It
seems that there is no clinical correlation but according to some
authors the presence of BRAF V600E is associatedwith an increased
risk of recurrence [1,9,10]. The thymus plays a major role in the
immune system development and it is composed of dendritic cells,
but its involvement in LCH has been reported to be rare. According
to our literature review the presence of thymus involvement was
noted in younger patients, with LCH multisystem disease and
higher mortality rate [4,12]. On the other hand, it has been sug-
gested that thymic involvement may be underestimated [11]. There
could be two plausible explanations for these underdiagnosed
rates. It could be that radiological ﬁndings are better evaluatedwith
thymic ultrasound andmediastinum computed tomography, which
are not routinely performed. Moreover, thymus involvement most
often is asymptomatic [4,13]. Our patient had self-healing cuta-
neous lesions and thymic involvement, without any other severe
manifestations. With the current evidence we are unable to predict
the prognosis of involvement of the thymus in neonatal LCH. We
suggest that a regular thymic ultrasound study, which is a non-
invasive technique, would allow us to know the incidence of
thymic involvement and its role on prognosis.Ethics statement
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